Startseite Adiponectin concentration in mid-trimester amniotic fluid varies with the α-amylase level and maternal and neonatal outcomes
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Adiponectin concentration in mid-trimester amniotic fluid varies with the α-amylase level and maternal and neonatal outcomes

  • Joseph Chervenak , Mio Sawai , Lamis El Kabab , Rahul Lohana , Daniel Skupski und Steven S. Witkin EMAIL logo
Veröffentlicht/Copyright: 14. Juli 2017

Abstract

Objective:

Factors influencing intraamniotic adiponectin levels and their functional significance remain incompletely elucidated. We prospectively measured adiponectin in amniotic fluid and identified its associations with maternal parameters, mediators in amniotic fluid and pregnancy outcomes.

Study design:

Mid-trimester amniotic fluid from 571 women was tested for adiponectin, interleukin (IL)-6, IL-8 and α-amylase by enzyme-linked immunosorbant assay (ELISA), after which clinical data were obtained. Correlations between adiponectin and clinical or laboratory variables were analyzed by the Kruskal-Wallis, Mann-Whitney and Spearman rank correlation tests.

Results:

As compared to median levels in 462 women with a term delivery (7.8 ng/mL), adiponectin was elevated in 14 women who subsequently developed preterm premature rupture of membranes (pPROM) (17.3 ng/mL) and 24 women with an iatrogenic preterm birth (IPTB) (13.9 ng/mL) (P=0.0003), but not in 30 women who subsequently had a spontaneous preterm birth with intact membranes (8.1 ng/mL) (P>0.05). Median adiponectin was also elevated in 13 women whose babies developed fetal growth restriction (FGR) (20.6 ng/mL) (P=0.0055) and in 22 women whose babies had respiratory distress syndrome (RDS) (23.0 ng/mL) (P<0.0001). The adiponectin concentration was positively correlated with amylase (P=0.0089) and inversely correlated with maternal body mass index (P=0.0045).

Conclusion:

Adiponectin is a component of mid-trimester amniotic fluid and its concentration varies with maternal body mass index and subsequent development of pPROM, IPTB, FGR and RDS.


Corresponding author: Dr. Steven S. Witkin, Division of Immunology and Infectious Diseases, Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA, Tel.: +(212) 746 3165, Fax: +(212) 746 8799

  1. Author’s statement

  2. Conflict of interest: Authors state no conflict of interest.

  3. Material and methods: Informed consent: Informed consent has been obtained from all individuals included in this study.

  4. Ethical approval: The research related to human subject use has complied with all the relevant national regulations, and institutional policies, and is in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.

References

[1] Goldfine AB, Kahn CR. Adiponectin: linking the fat cell to insulin sensitivity. Lancet 2003;362:1431–2.10.1016/S0140-6736(03)14727-7Suche in Google Scholar

[2] Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293–300.10.1530/eje.0.1480293Suche in Google Scholar PubMed

[3] Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.10.1210/jcem.86.5.7463Suche in Google Scholar PubMed

[4] Kinalski M, Telejko B, Kuzmicki M, Kretowski A, Kinalska I. Tumor necrosis factor α system and plasma adiponectin concentration in women with gestational diabetes. Horm Metab Res. 2005;37:450–4.10.1055/s-2005-870238Suche in Google Scholar PubMed

[5] Williams MA, Qiu C, Muy-Rivera M, Vadachkoria S, Song T, Luthy DA. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. J Clin Endocrinol Metab. 2004;89:2306–11.10.1210/jc.2003-031201Suche in Google Scholar PubMed

[6] Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Wiser A, Schiff E, et al. Maternal serum adiponectin levels during human pregnancy. J Perinatol. 2007;27:77–81.10.1038/sj.jp.7211639Suche in Google Scholar PubMed

[7] Baviera G, Corrado F, Dugo C, Cannata ML, Russo S, Rosario DA. Midtrimester amniotic fluid adiponectin in normal pregnancy. Clin Chem. 2007;53:1723–4.10.1373/clinchem.2007.088542Suche in Google Scholar PubMed

[8] Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Erez O, Mittal P, et al. Adiponectin in amniotic fluid in normal pregnancy, spontaneous labor at term, and preterm labor: a novel association with intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med. 2010;23:120–30.10.3109/14767050903026481Suche in Google Scholar PubMed PubMed Central

[9] Sivan E, Mazaki-Tovi S, Pariente C, Efraty V, Schiff E, Henri R, et al. Adiponectin in human cord blood: relation to fetal birth weight and gender. J Clin Endocrinol Metab. 2003;88:5656–60.10.1210/jc.2003-031174Suche in Google Scholar PubMed

[10] Aye ILMH, Powell TL, Jansson T. Review: adiponectin – The missing link between maternal adiposity, placental transport and fetal growth? Placenta 2013;34(Suppl A):27:540–5.10.1016/j.placenta.2012.11.024Suche in Google Scholar PubMed PubMed Central

[11] Caminos JE, Nogueiras R, Gallego R, Bravo S, Tovar S, Garcia-Caballero T, et al. Expression and regulation of adiponectin and receptor in humn and rat placenta. J Clin Endocrinol Metab. 2005;90:4276–86.10.1210/jc.2004-0930Suche in Google Scholar

[12] McDonald EA, Wolfe MW. Adiponectin attenuation of endocrine function within human term trophoblast cells. Endocrinol 2009;150:4358–65.10.1210/en.2009-0058Suche in Google Scholar

[13] Wang Y, Lu G, Wong WP, Vliegenthart JF, Gerwig GJ, Lam KS, et al. Proteomic and functional characterization of endogenous adiponectin purified from fetal bovine serum. Proteomics 2004;4:3933–42.10.1002/pmic.200400826Suche in Google Scholar

[14] Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144:768–73.10.1016/0002-9378(82)90349-0Suche in Google Scholar

[15] Doubilet PM, Benson CB, Nadel AS, Ringer SA. Improved birth weight table for neonates developed from gestations dated by early ultrasonography. J Ultrasound Med. 1997;16:241–9.10.7863/jum.1997.16.4.241Suche in Google Scholar

[16] Rosario FJ, Schumacher MA, Jiang J, Kanai Y, Powell TL, Jansson T. Chronic maternal infusion of full-length adiponectin in pregnant mice down-regulates placental amino acid transporter activity and expression and decreases fetal growth. J Physiol. 2012;590:1495–509.10.1113/jphysiol.2011.226399Suche in Google Scholar

[17] Aye IL, Gao X, Weintraub ST, Jansson T, Powell TL. Adiponectin inhibits insulin function in primary trophoblasts by PPARα-mediated ceramide synthesis. Mol Endocrinol. 2014;28:512–24.10.1210/me.2013-1401Suche in Google Scholar

[18] Wolf RO, Taussig LM. Human amniotic fluid isoamylases. Functional development of fetal pancreas and salivary glands. Obstet Gynecol. 1973;41:337–42.Suche in Google Scholar

[19] Fernandez De Castro A, Usategui-Gomez M, Spellacy WN. Amniotic fluid amylase. Am J Obstet Gynecol. 1973;116:931–6.10.1016/S0002-9378(16)33839-XSuche in Google Scholar

[20] Dessi A, Pravettoni C, Marincola FC, Schirru A, Fanos V. The biomarkers of fetal growth in intrauterine growth retardation and large for gestational age cases: from adipocytokines to a metabolomics all-in-one tool. Expert Rev Proteomics. 2015;12:309–16.10.1586/14789450.2015.1034694Suche in Google Scholar PubMed

Received: 2017-3-21
Accepted: 2017-6-12
Published Online: 2017-7-14
Published in Print: 2018-4-25

©2018 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Editorial
  4. Corner of Academy
  5. Peripartum cardiomyopathy – from pathogenesis to treatment
  6. Original articles – Obstetrics
  7. Is forty the new thirty? Population based study of advanced maternal age
  8. The laboratory control of anticoagulant thromboprophylaxis during the early postpartum period after cesarean delivery
  9. Epidural analgesia at trial of labor after cesarean (TOLAC): a significant adjunct to successful vaginal birth after cesarean (VBAC)
  10. Postpartum infection in relation to maternal characteristics, obstetric interventions and complications
  11. A technological advance for 21st century obstetricians: the electronically-controlled vacuum extractor
  12. Five years’ experience in an anesthesiology antenatal clinic for high-risk patients
  13. Clinical analyses of 383 cases with maternal cardiac diseases
  14. Induction of labor in patients with an unfavorable cervix after a cesarean using an osmotic dilator versus vaginal prostaglandin
  15. The misoprostol vaginal insert compared with oral misoprostol for labor induction in term pregnancies: a pair-matched case-control study
  16. Adiponectin concentration in mid-trimester amniotic fluid varies with the α-amylase level and maternal and neonatal outcomes
  17. Placental examination in nonmacerated stillbirth versus neonatal mortality
  18. Neurodevelopmental outcome at the age of 4 years according to the planned mode of delivery in term breech presentation: a nationwide, population-based record linkage study
  19. An observation of umbilical coiling index in a low risk population in Nigeria
Heruntergeladen am 24.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpm-2017-0094/html
Button zum nach oben scrollen